Politics

Q&A: Invest in safety and make savings overall — interview with Don Berwick

The author of the 2013 report which looked at patient safety in the NHS after the Mid Staffordshire Hospital scandal speaks to Jenny Bryan to share his thoughts on whether progress has been made.…

Your RPS needs you

Show your passion and dedication to pharmacy by putting yourself forward for this year’s RPS national pharmacy board elections.…

Recommendations made in Murray’s review for community pharmacy will not be simple to implement

Practical challenges, including building closer relationships with GPs, will need to be overcome if the recommendations in the Murray review on community pharmacy are to be implemented successfully.…

Editing The Pharmaceutical Journal

We, the undersigned, are pressing for the restoration of the post of editor for The Pharmaceutical Journal. We believe that the The Pharmaceutical Journal needs to be refocused and that the recent departure of its publisher presents an ideal opportunity to review the situation. One of us …

No more delays with rebalancing medicines legislation and pharmacy regulation

We need fewer empty promises and more action and progress with rebalancing medicines legislation and pharmacy regulation — particularly around dispensing errors.…

Preserving research and development in a post-Brexit era

Additional funding for R&D post-Brexit is a welcome move from the UK government, but there are other related issues to consider as well.…

A potted history of cannabis in the United States

Marijuana: a short history by John Hudak.…

Vaccines: under threat by the post-truth populist movement

In a climate where science and facts appear to play second fiddle to post-truth rants on social media, Cynthia Leifer explains why activism and public engagement must become part of the everyday work of scientists and physicians.…

The Pharmaceutical Journal’s most read opinion pieces of 2016

A round up of the most popular opinion pieces of 2016.…

What impact president-elect Donald Trump will have on the US healthcare system

William Seligman takes a look at what might happen to the US healthcare system and pharma under a Trump presidency.…